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a b s t r a c t
Introduction: Three factors that effect burn mortality are age, total body surface of burn (TBSA),
and inhalation injury. Of the three, inhalation injury is the strongest predictor of mortality
thus its inclusion in the revised Baux score (age+TBSA+17* (inhalation injury, 1=yes, 0=no)).
However, the weighted contribution of specific comorbidities such as smoker status on
mortality has traditionally not been accounted for nor studied in this subset of burn patients.
We therefore sought to examine the impact of current tobacco and/or marijuana smoking in
patients with inhalation injury.
Methods: A retrospective analysis of patients admitted to a regional burn center from 2002 to
2012. Independent variables analyzed included basic demographics, burn mechanism,
presence of inhalation injury, TBSA, pre-existing comorbidities, and smoker status. Bivariate
analysis was performed and logistic regression modeling using significant variables was
utilized to estimate odds of mortality.
Results: There were a total of 7640 patients over the study period. 7% (n=580) of the burn
cohort with inhalation injury were included in this study. In-hospital burn mortality for
inhalation injury patients was 23%. Current smokers (20%) included cigarette smokers and
marijuana users, 19% and 3%, respectively. Preexisting respiratory disease (17%) was present
in 36% of smokers compared to 13% of non-smokers (p<0.001). Smokers had significantly
lower mortality rate (9%) compared to non-smokers (26%, p<0.01). The logistic regression
model for mortality outcomes identified statistically four significant variables: age, TBSA,
ethnicity, and smoker status (OR=0.41, 95% CI=0.18–0.93). Presence of comorbidities,
including preexisting respiratory disease, was not significant.
Conclusion: In the sub group of burn patients with inhalation injury, the odds of mortality
significantly decreased in pre-existing smokers after adjusting for significant covariates. We
postulate that an immune tolerance mechanism that modulates and diminishes the pro-
inflammatory response confers a survival advantage in smokers after exposure to acute
smoke inhalation injury. Future prospective studies in human and/or animal models are
needed to confirm these findings.
a r t i c l e i n f o
Article history:






* Corresponding author at: UNC School of Medicine, University of North Carolina, 4008 Burnett Womack Building, CB 7228, United States.
Fax: +1 919 9660369.
E-mail address: anthchar@med.unc.edu (A. Charles).
http://dx.doi.org/10.1016/j.burns.2016.09.003
1. Introduction
Burn is one of the most devastating traumatic injuries
affecting an estimated 486,000 people in the United States in
2015 [1]. Advancements over the past three decades in burn
care such as measured fluid resuscitation, improved critical
care management, and early excision and grafting have
resulted in improved burn outcomes. Despite these advances,
the three major determinants of increased burn mortality
include age>60years old, % total body surface area (%TBSA)
>40%, and presence of inhalation injury [2–5]. Inhalation injury
is considered to be the strongest predictor of burn mortality
[2,4]. To better prognosticate burn outcomes, the Baux score
was created [6,7], however, to account for the weighted
contribution of inhalational injury to burn mortality, it was
later revised to include this predictor variable (age+percent
burn+17*) (inhalation injury, 1=yes, 0=no) [8,9]. More recently,
with the recognition of increased longevity of the US
population and its health related sequelae, it is paramount
that future burn mortality prediction models account for pre-
existing comorbidities in the prognostication of injury out-
comes. Specifically the role of pre-existing respiratory disease
markers such as smoking in the subset of burn patients with
inhalational injury.
Smoking is the single largest preventable cause of death
and disease in the United States [10]. It was estimated in 2014,
that 16.8% (40 million) adults in the United States are current
smokers of tobacco or marijuana. Of which 30.7 million
smoked every day. Majority of smokers range between 18 and
64 years of age. There are a variety of harmful substances in
tobacco smoke and marijuana that impair mucociliary
clearance, damage the cell lining of the trachea, bronchus
and bronchioles, and kill cells in the lungs that are responsible
for removing dust and bacteria leading to more mucus
production [11–15]. Toxins liberated during smoking can cause
damage to lung airways and alveoli leading to emphysema,
and chronic bronchitis [16,17]. Marijuana also can suppress the
immune system that could lead to increased risk of lower
respiratory tract infection in these smokers [16].
There have been no previous studies examining the
independent effect of smoking on burn mortality in patients
with inhalation injury. As the pathologic pulmonary manifes-
tation of smoking is akin to chronic inhalational injury, we
hypothesize that there will be an increased mortality in burn
patients with inhalational injury that are current smokers at
the time of the injury as compared to non-smokers.
2. Methods
This is a retrospective study of all burn patients admitted to the
University of North Carolina Jaycee Burn Center from 2001 to
2012. The North Carolina Jaycee Burn Center at UNC was
established in 1981 and averages more than 1200 acute
admissions per year. The burn center is a single unit, 36-bed
facility that has been verified by the American Burn Associa-
tion for pediatric and adult care.
The medical records of subjects identified by the UNC Burn
database query were reviewed to verify baseline demographic
data, injury characteristics, and provide detailed information
and associated preexisting comorbidities. Injury character-
istics of interest included burn etiology, %TBSA burn, presence
of inhalation injury, and intubation status on admission to the
burn center. Inhalation injury diagnosis is based on history
and confirmed by fiberoptic bronchoscopy examination per
our clinical protocol. Per National Burn Data Standards (NBDS)
created by the American Burn Association, inhalation injury is
recorded in the burn registry as either absent or present with
and without cutaneous burn based on medical records. Other
useful modalities such as chest-computed tomography (CT),
radionuclide imaging with 133Xenon, carbon monoxide levels
and pulmonary function testing results are not part of our
inhalational injury protocol.
Preexisting comorbidities were weighted using the Charl-
son Comorbidity Index (CCI) score [18,19]. The score is the
weighted sum of comorbid conditions. There are 17 comorbid
conditions included in the score and each is assigned a weight
from 1 to 6 points (Table 1). Pre-existing comorbidities were
identified utilizing the National Trauma Data Bank (NTDB)
from the American College of Surgeons Committee on Trauma.
Current smoking status was obtained from medical records
and recorded into the burn registry. Smoking status is reported
from patient, family member, or persons living with the
patient or with intimate knowledge of patient’s smoking
habits upon admission to the burn center. In addition to
tobacco smoke, marijuana use information was enquired.
Our outcome of interest is in-hospital mortality in patients
with inhalation injury. Baseline patient and injury character-
istics were compared between groups for mortality and
smoker status using Analysis of Variance for continuous
variables and chi-squared for categorical variables. Kruskal–
Wallis test was used to compare medians. We employed both
bivariate analyses to determine the relative influence of
smoking on mortality among covariates. To determine odds
of mortality, we used a multivariate logistic regression model
controlling for pertinent confounders (age, TBSA, ethnicity,
Table 1 – Charlson Comorbidity Index score system.
Comorbidity Score
Myocardial infarction 1
Congestive heart failure 1
Peripheral vascular disease 1
Cerebrovascular disease 1
Dementia 1
Chronic pulmonary disease 1
Rheumatologic disease 1
Peptic ulcer disease 1
Mild liver disease 1
Diabetes without chronic complications 1
Diabetes with chronic complications 2
Hemiplegia or paraplegia 2
Renal disease 2
Any malignancy, including leukemia and lymphoma 2
Moderate or severe liver disease 3
AIDS/HIV 6
Metastatic solid tumor 6
Maximum comorbidity score 33
CCI, and smoker status). A comparison of Area Under the
Receiver Operating Characteristic (AUROC) curve between
regression models was done with current smokers and non-
smokers to determine accuracy of including smoker status in
predicting burn mortality. Stata/MP (Version 12) (Statacorp,
College Station, TX) was used for all data management and
statistical analysis. The University of North Carolina Institu-
tional Review Board approved this study.
3. Results
3.1. Patient demographic
A total of 7640 patients were admitted to the hospital during
the study period. Only a subset of 580 patients had inhalation
injury and thus met criteria for analysis in this study. The
mean age was 4420years and a male predominance (n=395,
68%). Caucasians made up 56% of the population. The most
common mechanism of burn was flame (n=536, 93%)
compared to scald and other injury, 3% and 4% respectively.
The mean TBSA for this inhalation injury cohort was 22
(SD=24%) with a median of 13% (Table 2). There was no
significant difference in TBSA based on ethnicity or gender.
The mean length of hospitalization, ICU stay, and mechanical
ventilation days was 36.946.4days, 28.436.4days, and 21.4
31.3days respectively. Current smokers (20%) with inhala-
tion injury included tobacco smokers and marijuana users,
19% and 3%, respectively. Thirty-two percent of inhalation
injury patients had comorbidities. Preexisting respiratory
disease was present in 17% of inhalation injury burn patients.
3.2. Bivariate analysis for burn inhalation injury patients
During the study period, the mortality rate in inhalation injury
patients was 23%. The mean age of survivors vs. non-survivors
was 41.219.1years and 55.019.8years, respectively (Ta-
ble 3). TBSA was significantly associated with mortality
(p<0.001). The average TBSA for patients who died was 46.9
28.3%. Men represented 61% of non-survivors compared to
women at 39% (p<0.05). Ethnicity and mechanism of burn had
no significant impact on mortality. Length of hospital stay for
non-survivors was significantly shorter (p<0.01). ICU stay and
days on mechanical ventilation were not significant.
3.3. Smoker status analysis
A separate bivariate analysis was performed to compare
smokers and non-smokers. The mean age for current smokers
vs. non-smokers was 49.014.5years and 43.221.2years,
respectively (p<0.001) (Table 4). The average TBSA for smokers
was significantly lower than non-smokers (12.116.1% vs. 24.4
25.3%, p<0.001). Current smokers had a higher CCI score
(0.961.33) compared to non-smokers (0.611.26, p<0.01).
Caucasians were predominant in both groups and were more
likely to be smokers compare to minorities (68% vs. 32%,
p<0.05). Smokers had a significantly lower mortality rate than
non-smokers (9% vs. 26%, p<0.001). There was no statistically
significant difference in gender, mechanism of injury, length
Table 2 – Patient characteristics.
Patient characteristics
(n=580)






















Overall mean 22.0 (24.2)
By gender
Male 395 23.2 (24.6)













Overall mean 28.4 (36.4)
Hospital stay
Overall mean 36.9 (46.4)
Mechanical ventilation
Overall mean 481 21.4 (31.3)
By gender
Male 329 22.9 (31.9)
Female 150 18.4 (29.9)
By ethnicity
White 257 18.0 (27.7)
Other 210 25.7 (34.8)
TBSA: % total body surface area burn.
of hospitalization, ICU stay, and days on mechanical ventila-
tion between current smokers and non-smokers.
A multivariate logistic regression performed for mortality
outcome controlling for statistically significant covariates on
bivariate analysis: age, TBSA, ethnicity, comorbidities using
Charlson Comorbidity Index revealed a decreased odds of
mortality in smokers (OR=0.41, 95% CI=0.18–0.93) (Table 5).
Examining mortality over length of hospitalization in first 100
days, the predicted mortality at 30days is significantly lower
for smokers (8%) compared to non-smokers (17%) (Fig. 1).
Comparison of AUROC was done on logistic regression models
with smokers and nonsmokers to determine accuracy of this
variable in predicting mortality over length of hospitalization.
There was a significant difference between smokers
(AUROC=0.870, 95% CI=0.833–0.907) and nonsmokers
(AUROC=0.899, 95% CI=0.867–0.931, p<0.01).
4. Discussion
No previous studies have examined the independent influence
of current smoking on mortality following burn inhalation
injury. In this study, we have established that in patients with
burn inhalation injury, there is a 50% decrease in odds of
mortality in current smokers compared to nonsmokers.
Cigarette smoke or indeed smoke from a fire produces a
smoke with more than 4000 noxious and toxic components,
including gas and particulate matter such as a formaldehyde,
carbon monoxide, nicotine acetaldehyde, phenol and potassi-
um cyanide. Smoke-related toxins damage epithelial and
capillary endothelial cells of the airway [20]. Smoke induced
irritation of the trachea and larynx and Inhaled particulate
matter is deposited in the respiratory tract results in
breathlessness due to swelling and narrowing of lung airways,
with impairment of the pulmonary mucociliary clearance
system and associated impaired bacterial clearance can lead to
increased risk of pneumonia, decrease production of surfac-
tant, and permanent damage to alveoli [21–24].
Following acute inhalation injury, the early inflammatory
changes occur in the smoke naïve airway, followed by a period
of diffuse exudate formation and progressive bronchiolar
edema. Furthermore, the combination of necrotizing
Table 3 – Bivariate analysis of burn patients with
inhalation injury.
Live Dead p-Value
Age 41.2 (19.1) 55.0 (19.8) <0.001
TBSA 14.5 (SD=16.7) 46.9 (SD=28.3) <0.001
CCI 0.60 (0–7) 0.95 (0–6) 0.004
Ethnicity
White 54% 60% 0.236
Other 46% 40%
Gender







Smoker 23% 8% <0.001
Non-smoker 77% 92%
Respiratory disease
Pre-existing 17% 17% 0.950
None 83% 83%
ICU stay 29.5 (35.9) 24.9 (38.2) 0.187
LOS 40.4 (47.9) 24.8 (38.4) <0.001
Mechanical ventilation 21.1 (29.4) 23.0 (37.1) 0.553
TBSA: total body surface area.
CCI: Charlson Comorbidity Index.
LOS: length of hospital stay.
Table 4 – Bivariate analysis of burn patients with
inhalation injury (smokers vs. non-smokers).
Smoker Non-smoker p-Value
Age 49.0 (14.5) 43.2 (21.2) 0.005
TBSA 12.1 (SD=16.1) 24.4 (SD=25.3) <0.001
CCI 0.96 (1.33) 0.61 (1.26) 0.003
Ethnicity
White 68% 53% 0.010
Other 32% 47%
Gender







Pre-existing 36% 13% <0.001
None 64% 87%
In-hospital mortality 9% 26% <0.001
ICU stay 28.3 (39.5) 28.4 (35.6) 0.962
LOS 37.0 (49.3) 36.9 (45.6) 0.879
Mechanical ventilation 23.0 (35.8) 21.1 (30.1) 0.546
TBSA=total body surface area.
CCI=Charlson Comorbidity Index.
LOS=length of hospital stay.
Table 5 – Multivariate logistic regression for mortality in
burn cohort.
Variable Adjusted odds ratio,
95% confidence interval (CI)
p-Value
Age 1.06 (1.04–1.08) <0.001
TBSA 1.08 (1.06–1.09) <0.001
Ethnicity 2.00 (1.14–3.48) 0.015
CCI 1.16 (0.96–1.41) 0.123
Smoker status 0.41 (0.18–0.92) 0.031
TBSA=total body surface area.
CCI=Charlson Comorbidity Index.
bronchitis, bronchial swelling, and bronchospasm that causes
obstruction of large and small airways and increased capillary
permeability, which magnifies airway and pulmonary edema
and increase morbidity and mortality [25–27]. This pathologic
response is mediated through innate immune cells like
monocytes/macrophages that detect and respond to “danger
signals” (e.g. smoke, tissue damage) through pattern recogni-
tion receptors expressed on their surface and modulated by
Toll like receptor 4 (TLR4) [28,29].
The detection of smoke and chemical toxins by innate
immune cells triggers a robust and essential pro-inflammatory
response that leads to extensive tissue damage. This early and
exuberant inflammatory changes that occur in the smoke
naïve airway, followed by a period of diffuse exudate
formation and progressive bronchiolar edema may be absent
in current smokers.
Pathophysiological adaptations to regulate over-exuberant
inflammation serve as an important mechanism for host
protection against toxin exposure. One of the classic examples
of such a protective mechanism is endotoxin tolerance, a
phenomenon in which cells or organisms exposed to low
concentrations of endotoxin such as Lipopolysaccharide enter
into a transient unresponsive state and are unable to respond
to larger challenges with endotoxin [30,31]. We posit that in
chronic smokers, this same adaptive immunologic tolerance
mechanism may have developed as a result of chronic smoke
exposure and is protective during acute smoke inhalation
injury. Long-term smokers have demonstrated a chronic, low-
grade inflammation. After long-term tobacco smoke exposure
(15–84 weeks) some studies found suppressed cell-mediated
immunity [32,33]. The influence of the acute inhalation of
smoke particle and toxins within the milieu of a chronically
smoke exposed airway and pulmonary parenchyma results in
a mooted inflammatory response and a survival advantage
[34,35].
Another protective mechanism that have been described
previously in studies that may explain our findings is the
presence of an anti-inflammatory substance found in cigarette
smoke such as Carbon monoxide (CO) [36,37]. High concen-
trations of CO can induce apoptosis and inhibit respiratory
enzyme functions [38]. However, administered at low con-
centrations, CO has shown to be cyto-protective and diminish
the inflammatory response by down regulating pro-inflam-
matory cytokines and the up-regulation of the anti-inflamma-
tory cytokine interleukin-10 [39,40]. Furthermore, Smokers
have been much higher levels of Heme Oxygenase-1 (HO-1), an
enzyme that oxidizes heme to CO, observed in the airways
than in nonsmokers and are exposed to chronic low-levels of
CO through long-term use which may explain a diminished
inflammatory response following acute inhalation injury in
current smokers [36]. HO-1 has been implicated in cyto-
protection in many acute lung injury models [41].
The limitations of this study are those inherent to any study
with a retrospective. This is a single center study, but our large
sample size obviates the loss of generalizability of our findings.
The contribution of frailty and its effect on outcome was not
evaluated. Furthermore, the Charlson Comorbidity Index was
originally based on the predictive power to estimate mortality
in medicine patients and was never intended to general-
izations to surgical or burn cohort. Most importantly, Inhala-
tion injury was analyzed as an all or none variable. The degree
of inhalation injury and the heterogeneity of smoke inhaled
are unknown. According to the NBDS, carbon monoxide levels
can provide information regarding injury severity and risk for
adverse outcomes. However, a low carboxyhemoglobin does
not always indicate a minimal smoke exposure because
administration of oxygen at the scene of the fire can displace
some of the carbon monoxide before arrival in the emergency
department. We agree pre-hospital information is unavailable
in our registry and there is a small likelihood of presentation or
Fig. 1 – Predicted probability of mortality for current and non-smokers with inhalation injury.
survivor bias. Based on American Burn Association guidelines,
most burns are automatic referred to our regional burn center
and we believe we capture a preponderance amount of severe
burn patients with and without inhalation injury. Like any
other trauma surveillance registry, we do not and cannot
capture death at the scene. Lastly, the chronicity of smoking
and the pack year history of smokers where not controlled for
in our analysis as that data was not available.
5. Conclusion
In the sub group of burn patients with inhalation injury, the
odds of mortality significantly decreased in pre-existing
smokers after adjusting for significant covariates. We postu-
late that an immune tolerance mechanism that modulates and
diminishes the pro-inflammatory response confers a survival
advantage in smokers after exposure to acute smoke inhala-
tion injury. A prospective study is needed to better character-
ize our findings and molecular mechanism on the interaction
of smoking and adaptive immune response is imperative.
There needs to be future prospective studies in human and/or
animal models to take in account varying degrees of inhalation
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